About the Medication Adherence Working Group
Optimal medication adherence is crucial for improved clinical and health outcomes. Medication adherence is defined as “the process by which patients take their medications as prescribed”. For rheumatic diseases, however, up to 85% of the patients do not fully adhere to their medication regimen.
The Outcome Measures in Rheumatology Adherence Working Group (OMERACT-Adherence Group) is currently developing a core domain set for trials of medication adherence interventions in patients with rheumatic diseases. The group consists of patients, healthcare professionals, researchers and other stakeholders. Their activities comprise: (1) a systematic literature review of outcome domains in medication adherence intervention trials in rheumatology, (2) interviews with patients and caregivers to identify their views on core domains, (3) nominal group technique with patients and caregivers to prioritise outcome domains, (4) an international modified Delphi study to define a preliminary core domain set, and (5) a consensus workshop to finalise a core domain set.

Susan Bartlett
Co-Chair

Maarten de Wit
Co-Chair

Ayano Kelly
Co-Chair

Kathleen Tymms
Co-Chair
Willemina Campbell
PRP
Alison Hoens
PRP
Vicki Evans
PRP
Michael Gill
PRP
Sharon Lee
PRP
Dawn Richards
PRP
Marieke Scholte-Voshaar
PRP
Delphi Survey
We are inviting you to participate in The Outcome Measures in Rheumatology – Interventions for Medication Adherence (OMERACT-Adherence) project which aims:
- to improve the quality of medication adherence research in rheumatology
- to ensure that medication adherence trials in rheumatology consistently report outcomes that are meaningful and relevant to all stakeholders
To learn more about this project, please visit these resources:
- The infographic gives an introduction to the survey: Infographic
- The 3-minute videoexplains why we are doing this research: Video 1
- The 6-minute videoexplains what outcomes are, and how to do the survey: Video 2
The survey will include 3 rounds of online questionnaires, sent about 1-2 months apart, each taking approximately 15 minutes to complete.
Please click here or scan the QR code for more information about the survey, and to get started: https://redcap.link/omeract.med
As we wish to include the opinions of patients, health professionals, researchers (with expertise in either medication adherence research, or outcomes research), and other stakeholders (journal editors, research funders, pharmaceutical industry representatives, pharmaceutical regulators and policy makers) from across the world, we also ask you/your organisation to disseminate the Delphi survey. Please share the attached flyer with your colleagues/membership/network(e.g. post on your website and/or share via your mailing list).
If you are interested in finding out more about the work of OMERACT visit www.omeract.org and www.omeracthandbook.org.
If you have any questions, please contact Dr Ayano Kelly ([email protected]). Thank you for considering our request.
Sincerely, Dr Ayano Kelly
On behalf of the OMERACT-Adherence Special Interest Group
(The primary research hub for this study is in Sydney, Australia, and the primary study sponsor is South Western Sydney Local Health District)
Working Group Members:
Rieke Alten
Eindra Aung
Christine Bailey
Susan Bartlett
Dorcas Beaton
Charlotte Bekker
Paul Bird
Willemina Campbell
Loreto Caromona
Robin Christensen
Ethan Craig
Therese Dawson
Ric Day
Mary De Vera
Maarten de Wit
Vicki Evans
Caroline Flurey
Michael Gill
Geraldine Hassett
Renske Hebing
Catherine Hill
Helen Keen
Ayano Kelly
Sharon Lee
Sabrina Mai Nielson
Lyn March
Lara Maxwell
Alexa Meara
Francois Nantel
Pongthorn Narongroeknawin
Jose Negron
Robby Nieuwlaat
Alison Hoens
Dawn Richards
Shahrzad Salmasi
Elizabeth Salt
Marieke Scholte-Voshaar
Yomei Shaw
Bev Shea
Jas Singh
Rani Sinnathurai
Maria Suarez-Almazor
Daniel Sumpton
Allison Tong
Karine Toupin April
Peter Tugwell
Kathleen Tymms
Bart Van den Bemt
Suzanne Verstappen
Luke Williamson
Peter Wong
David Lam
James Bluett